The atopic dermatitis treatment ‘Adtralza’ is entering its final stages of receiving reimbursement in Korea.

According to industry sources, the Ministry of Health and Welfare recently issued a negotiation order for Leo Pharma Korea’s interleukin-13 (IL-13) inhibitor for atopic dermatitis, Adtralza (tralokinumab). Under the order, the company will soon start pricing negotiations with the National Health Insurance Service.

Adtralza was approved in Korea in August this year, and its reimbursement agenda passed the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee review earlier this month.

More specifically, the drug is indicated for